This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spreghini, E.
Right arrow Articles by Barchiesi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spreghini, E.
Right arrow Articles by Barchiesi, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2008, p. 513-517, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.01447-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B{triangledown}

Elisabetta Spreghini,1 Carmelo Massimo Maida,2 Maria Eleonora Milici,2 Giorgio Scalise,1 and Francesco Barchiesi1*

Istituto di Malattie Infettive e Medicina Pubblica, Università Politecnica delle Marche, Ancona,1 Dipartimento di Igiene e Microbiologia "D'Alessandro," Università degli Studi di Palermo, Palermo, Italy2

Received 7 November 2007/ Accepted 27 November 2007

We evaluated the effects of sequential therapy with caspofungin (CAS) or amphotericin B (AMB) followed by posaconazole (POS) against Candida glabrata. The susceptibilities to POS of yeast cells pre-exposed to CAS or AMB were identical to those of untreated cells as shown by standard Clinical and Laboratory Standards Institute broth dilution, cell viability, and disk diffusion methods. We then investigated the activity of sequential regimens in an experimental model of disseminated candidiasis. CAS given at 1 mg/kg/day for 2 days followed by POS at either 15 or 30 mg/kg/day significantly reduced the counts compared to the controls, but this treatment was not superior to the use of CAS alone. Also, sequential regimens with AMB given at 1 mg/kg/day for 2 days followed by POS (AMB/POS) were effective at reducing the fungal burden against the controls. In addition, AMB/POS with both doses of the triazole were significantly more effective than AMB alone. Overall, our data showed that there is no therapeutic advantage in using CAS followed by POS, whereas an induction therapy with AMB followed by a maintenance regimen with POS might be a suitable strategy in managing C. glabrata infections.

* Corresponding author. Mailing address: Istituto di Malattie Infettive e Medicina Pubblica, Università Politecnica delle Marche, Azienda Ospedaliera-Universitaria, Ospedali Riuniti, Umberto I-G.M. Lancisi-G. Salesi, Via Conca 60020, Torrette di Ancona, Ancona, Italy. Phone: 39 071 5963426. Fax: 39 071 5963468. E-mail: f.barchiesi{at}univpm.it

{triangledown} Published ahead of print on 3 December 2007.

Antimicrobial Agents and Chemotherapy, February 2008, p. 513-517, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.01447-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ruan, S.-Y., Chu, C.-C., Hsueh, P.-R. (2008). In Vitro Susceptibilities of Invasive Isolates of Candida Species: Rapid Increase in Rates of Fluconazole Susceptible-Dose Dependent Candida glabrata Isolates. Antimicrob. Agents Chemother. 52: 2919-2922 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»